Our results show that EGFR, a receptor on the cell surface of many cells, also plays an active role in KRAS-mutated colorectal tumours - and in a different way than previously thought.

Natalie Staplin, PhD, of the University of Oxford in Oxford, UK, and colleagues pooled data from 23,340 patients with CKD, T2D, or HF at risk for acute eGFR dips with empagliflozin initiation from ...